Mankind Pharma Sees Sharp Open Interest Surge Amid Mixed Market Signals

Open Interest and Volume Dynamics

On 23 June 2026, Mankind Pharma’s open interest (OI) in derivatives rose sharply by 3,483 contracts, a 14.98% increase from the previous day’s 23,247 to 26,730 contracts. This notable expansion in OI was accompanied by a total volume of 46,483 contracts traded, indicating robust participation from traders and investors alike. The futures segment alone accounted for a value of approximately ₹12,929 lakhs, while options contributed an overwhelming ₹26,036.76 crores in notional value, culminating in a combined derivatives turnover of nearly ₹15,990 lakhs.

The underlying stock price closed at ₹2,537, slightly down by 0.03%, underperforming its sector by 1.3% and the Sensex by 0.61%. Despite this, the stock has maintained a positive momentum over the last day, registering a modest 0.23% gain in returns during this period. Intraday, the stock touched a high of ₹2,604, marking a 2.59% spike, suggesting bouts of buying interest amid the broader subdued price action.

Market Positioning and Moving Averages

Mankind Pharma’s price currently trades above all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a sustained uptrend in the medium to long term. This technical positioning often attracts momentum traders and institutional investors, which could explain the surge in open interest as participants position themselves for potential directional moves.

Investor participation has notably increased, with delivery volumes on 22 June rising by 110.27% to 4.54 lakh shares compared to the five-day average. This surge in delivery volume underscores genuine buying interest rather than purely speculative trading, lending credence to the bullish undertone despite the slight price dip on the day.

Interpreting the Open Interest Surge

The near 15% jump in open interest suggests that fresh positions are being established rather than existing ones being squared off. This typically indicates increased conviction among traders about the stock’s near-term direction. Given the mixed price action—intraday highs contrasting with a slight close decline—market participants may be hedging or speculating on volatility rather than a clear directional breakout.

Options market data further supports this view. The substantial notional value in options trading points to active call and put writing and buying, which often precedes significant price moves. The balance between futures and options turnover also highlights a diverse set of strategies at play, from directional bets to volatility plays and hedging.

Sector and Market Context

Within the Pharmaceuticals & Biotechnology sector, Mankind Pharma is classified as a mid-cap with a market capitalisation of ₹1,04,541.67 crores. The sector itself has been relatively resilient, but Mankind Pharma’s slight underperformance relative to its peers and the broader Sensex on the day suggests selective profit-taking or cautious positioning by investors.

However, the stock’s mojo score of 72.0, upgraded from a previous Hold to a Buy rating on 18 June 2026, reflects improving fundamentals and positive analyst sentiment. This upgrade likely contributed to the increased open interest as market participants recalibrated their positions in anticipation of further gains.

Liquidity and Trading Viability

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting a trade size of approximately ₹2.47 crores based on 2% of the five-day average. This ensures that institutional investors can enter or exit positions without significant market impact, which is crucial for sustaining the observed open interest growth.

Potential Directional Bets and Investor Outlook

The combination of rising open interest, strong volume, and technical positioning above key moving averages suggests that investors are positioning for an upward move in Mankind Pharma’s stock price. The recent mojo grade upgrade to Buy reinforces this positive outlook, signalling improving earnings prospects or favourable sector dynamics.

Nonetheless, the slight price underperformance on the day and the sector lag indicate that caution remains warranted. Investors may be balancing bullish bets with protective strategies, such as buying puts or writing calls, to hedge against volatility or sector-specific risks.

Overall, the derivatives market activity points to a nuanced market stance: a blend of optimism supported by fundamental upgrades, tempered by short-term profit-taking and risk management. This environment favours investors who closely monitor open interest trends and volume patterns to gauge the evolving market sentiment.

Conclusion

Mankind Pharma Ltd’s recent surge in open interest and trading volumes in the derivatives segment highlights a phase of active repositioning by market participants. While the stock’s price showed minor weakness relative to its sector and benchmark indices, the technical and fundamental indicators suggest a cautiously optimistic outlook. The upgrade in mojo grade to Buy and sustained investor participation underpin the potential for further gains, albeit with prudent risk management given the mixed signals.

Investors should continue to track open interest changes alongside price and volume dynamics to better understand the evolving market consensus and adjust their strategies accordingly.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →